Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

Recruiting now

Conditions studied: Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

In brief

The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).

Key facts

Study ID

NCT06058234

Run by

Centers for Medicare and Medicaid Services/ Coverage and Analysis Group

People needed

8680

Starts

2023-07-06

Expected to finish

2029-06-30

Last updated by the study team

2023-09-28

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.

You may not qualify if…

• none

Where it is running

• Centers for Medicare and Medicaid Services — Baltimore, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.